Most biotech startups talk about innovation while still running tests on animals and crossing their fingers that regulators will translate the data. Genoskin skipped the guessing game. The company takes human skin tissue, often discarded during plastic surgeries, and turns it into live exvivo testing platforms that stay viable for seven days. What looks like a waste product to most became the foundation for NativeSkin and HypoSkin, standardized models delivering predictive data that matters to pharma, biotech, medtech, and cosmetics companies worldwide. That shift isn’t theoretical. It’s the difference between hoping animal studies line up with human biology and actually starting with human biology.
Founded in 2011, Genoskin has split its footprint between Salem, Massachusetts, and Toulouse, France. Founder and CEO Pascal Descargues, PhD, with a doctorate in Pathophysiology and a business degree from Toulouse Business School, built the company on one simple observation: better answers come from better sources. With more than 490 clients a year, over 10,000 skin models produced annually, and integrated multi-omics and AI-driven analytics, the company is no longer proving its concept. It is scaling it.
That scaling just got a major boost. Genoskin announced an $8.7M Series A, its first external equity round. USD 5.4 million in equity and $3.3M in structured bank debt came together through a serious roster of backers. OCCTE’s FPCI Occidev Impacts, Captech Santé, GSO Innovation, and CA Toulouse 31 Initiatives led the equity side, with debt support from Bpifrance, BNP Paribas, Caisse d’Épargne Midi-Pyrénées, and Crédit Agricole.
The roadmap reads like a company gearing up for dominance. A 7,500 ft² lab in Salem slated for 2026. A 10,700 ft² facility in Toulouse in 2027. Automation to double production capacity, expand mast cell manufacturing for next-day delivery in the US, and immune-centric services launching by 2027. Headcount is set to double in the next three years, with strategic hiring in Europe and Asia beginning in 2026. Along the way, eight granted patents lock down Genoskin’s preservation matrices and explant methodologies.
The leadership team has the mix to make it work. Pascal Descargues, PhD driving vision, Frederick Roques managing financial growth, Vicky Tourte strengthening culture, Nicolas Gaudenzio, PhD advancing science, Anna Falkovsky scaling sales, and Lorna Santos, PhD steering research and product development. Together they’re not just running another CRO. They’re redefining how non-clinical testing gets done.
By 2034, the non-clinical testing market is projected to hit USD 155.4 billion. While others debate animal ethics or regulatory bottlenecks, Genoskin will keep delivering human-relevant data in standardized, ready-to-use kits. The future of testing isn’t somewhere down the line. It’s already alive and growing in Salem and Toulouse.
